Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion type Assertion NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_head.
- NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion description "[Notable examples include the dramatic benefit of chimeric antigen receptor gene-modified T cells redirected towards B-cell lineage antigen CD19 in patients with chronic lymphocytic leukemia, and the impressive outcomes in the use of TCR gene-modified T cells redirected towards NY-ESO-1, a representative cancer-testis antigen, in patients with advanced melanoma and synovial cell sarcoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_provenance.
- NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion evidence source_evidence_literature NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_provenance.
- NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion SIO_000772 24352938 NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_provenance.
- NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion wasDerivedFrom befree-20150227 NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_provenance.
- NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_assertion wasGeneratedBy ECO_0000203 NP334326.RAbGy5fHmhK9EdQECVYnPEDSsEblXZrTsBpRIsp5EqDmI130_provenance.